According to a recently published multisite, placebo‐controlled, double‐blind phase III study in the Journal of Diabetes Investigation, Mirogabalin in a dose-dependent manner exerts a significant efficacy to treat diabetic peripheral neuropathic pain (DPNP).

Eight hundred and thirty-four patients with DPNP of ≥20 years old selected and randomized to 2:1:1:1 to obtain placebo (n=330), Mirogabalin 15 (n=164), 20 (n=165) or 30 (n=165) mg/day for fourteen weeks along with a 1‐ to 2‐week titration. Differences in average daily pain score (ADPS) were evaluated as primary outcomes of the study.

A total of 755 accomplished the analysis. The patients received placebo, Mirogabalin 15, 20 or 30 mg/day showed −1.31, −1.34, −1.47 and −1.81 change in the least squares mean average daily pain score from the baseline, proving statistical significance for 30 mg/day Mirogabalin versus placebo. All the Mirogabalin groups manifest mild‐to‐moderate treatment‐emergent adverse events. Most common adverse events noticed was dizziness, somnolence, weight increase, nasopharyngitis, and peripheral edema. On the basis of all the findings, 30 mg/day Mirogabalin provides statistically significant pain relief with substantial tolerability.